CTT Pharmaceutical Holdings Management
Management criteria checks 3/4
CTT Pharmaceutical Holdings' CEO is Ryan Khouri, appointed in Feb 2022, has a tenure of 4.33 years. directly owns 13.36% of the company’s shares, worth $627.63K. The average tenure of the management team and the board of directors is 5.8 years and 11.5 years respectively.
Key information
Ryan Khouri
Chief executive officer
US$60.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | 13.4% |
| Management average tenure | 5.8yrs |
| Board average tenure | 11.5yrs |
Recent management updates
Recent updates
CEO
Ryan Khouri (46 yo)
Mr. Ryan Khouri is Chief Executive Officer of CTT Pharmaceutical Holdings, Inc. from February 22, 2022 and also serves as Director since February 2025 until 2026. Additionally, Mr. Khouri has CEO experienc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.3yrs | US$60.00k | 13.36% $ 627.6k | |
| Founder & Consultant | 19.4yrs | no data | 27.48% $ 1.3m | |
| Special Advisor & Senior VP of Commercial Development | 5.8yrs | no data | no data |
Experienced Management: CTTH's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 11.8yrs | no data | 3.97% $ 186.7k | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | 11.6yrs | no data | no data | |
| Member of Advisory Board | 11.4yrs | no data | no data | |
| Independent Director | 1.3yrs | no data | 6.36% $ 298.7k |
Experienced Board: CTTH's board of directors are seasoned and experienced ( 11.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/21 09:03 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CTT Pharmaceutical Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.